-
公开(公告)号：US11963947B2
公开(公告)日：2024-04-23
申请号：US17058903
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K9/16 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
CPC分类号： A61K31/4155 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/2095 , A61K9/2813 , A61K9/284 , A61K9/2866 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
摘要： Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.
-
公开(公告)号：US11992477B2
公开(公告)日：2024-05-28
申请号：US17058883
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K9/16 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
CPC分类号： A61K31/4155 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/2095 , A61K9/2813 , A61K9/284 , A61K9/2866 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
摘要： The present invention relates to a pharmaceutical combination, comprising a glucokinase activator or a pharmaceutically acceptable salt, isotopic label, crystal form, hydrate, solvate, diastereomer, or enantiomer thereof and an SGLT-2 inhibitor. The present invention further relates to a pharmaceutical composition, a fixed-dose combination preparation, and preparation methods and uses thereof.
-
公开(公告)号：US20210214312A1
公开(公告)日：2021-07-15
申请号：US17058929
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： C07D231/38 , A61K47/38 , A61P3/10
摘要： A pharmaceutical combination comprises a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotope labeled form thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof and an α-glucosidase inhibitor. A pharmaceutical composition, a fixed dose combination formulation, a preparation method for and the use of the pharmaceutical composition and the fixed dose combination formulation.
-
公开(公告)号：US20210196682A1
公开(公告)日：2021-07-01
申请号：US17058903
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K31/4985 , A61K31/403 , A61K31/40 , A61K9/28 , A61K9/20 , A61K31/522 , A61K9/16 , A61P3/10
摘要： Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.
-
公开(公告)号：US20240299357A1
公开(公告)日：2024-09-12
申请号：US18610100
申请日：2024-03-19
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K9/16 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
CPC分类号： A61K31/4155 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/2095 , A61K9/2813 , A61K9/284 , A61K9/2866 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
摘要： Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.
-
公开(公告)号：US20230346748A1
公开(公告)日：2023-11-02
申请号：US18311846
申请日：2023-05-03
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K31/4439 , A61K45/06 , A61K9/16 , A61K31/403 , A61K31/4985 , A61K9/20 , A61K31/522 , A61K31/40 , A61K31/7034 , C07D403/12 , C07D231/38 , A61K9/28 , A61K31/155 , A61P3/10 , A61K31/4035 , A61K47/38
CPC分类号： A61K31/4155 , A61K31/4439 , A61K45/06 , A61K9/1611 , A61K31/403 , A61K31/4985 , A61K9/2054 , A61K9/2013 , A61K9/1617 , A61K31/522 , A61K9/2009 , A61K9/2086 , A61K9/2095 , A61K31/40 , A61K31/7034 , C07D403/12 , A61K9/1635 , C07D231/38 , A61K9/2813 , A61K9/2866 , A61K31/155 , A61P3/10 , A61K31/4035 , A61K9/284 , A61K9/1694 , A61K47/38 , A61K9/2027
摘要： The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.
-
公开(公告)号：US20210212991A1
公开(公告)日：2021-07-15
申请号：US17058936
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K31/4439 , A61K31/4035 , A61K9/20 , A61K9/28 , A61K9/16
摘要： The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucose kinase activator or a pharmaceutical salt of same, an isotope marker of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed-dose compound preparation, and a preparation method for and uses of the pharmaceutical composition and of the fixed dose compound preparation.
-
公开(公告)号：US12064416B2
公开(公告)日：2024-08-20
申请号：US17058936
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K9/20 , A61K9/16 , A61K9/28 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
CPC分类号： A61K31/4155 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/2095 , A61K9/2813 , A61K9/284 , A61K9/2866 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
摘要： The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucose kinase activator or a pharmaceutical salt of same, an isotope marker of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed-dose compound preparation, and a preparation method for and uses of the pharmaceutical composition and of the fixed dose compound preparation.
-
公开(公告)号：US11666556B2
公开(公告)日：2023-06-06
申请号：US17058863
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K9/20 , A61K9/28 , A61K31/155 , A61P3/10 , A61K9/16 , A61K31/40 , A61K31/403 , A61K31/4985 , A61K31/522 , A61K31/4035 , A61K31/4439 , A61K31/7034 , C07D403/12 , A61K47/38 , C07D231/38 , A61K45/06
CPC分类号： A61K31/4155 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/2095 , A61K9/284 , A61K9/2813 , A61K9/2866 , A61K31/155 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/4439 , A61K31/4985 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K47/38 , A61P3/10 , C07D231/38 , C07D403/12
摘要： The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.
-
公开(公告)号：US20210220334A1
公开(公告)日：2021-07-22
申请号：US17058863
申请日：2019-05-28
发明人： Li Chen , Yongguo Li , Gaosen Wang , Huisheng Gao
IPC分类号： A61K31/4155 , A61K45/06 , A61K47/38
摘要： The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.017 秒)
